Article
Author(s):
Specialty drugs are a large driver of health care spending.
Express Scripts and Walgreens Boots Alliance recently announced a broadening of their purchasing efforts to include specialty brand drugs, according to a press release.
Due to the potential cost-savings associated with biosimilars in the next few years, the companies believe the expansion will have significant benefits.
"Specialty medications represent the most costly and complex drugs. By expanding our efforts with Walgreens Boots Alliance, we will improve our supply chain and ultimately make the use of these medicines, including biosimilars, more affordable and accessible for our patients and clients," said Tim Wentworth, CEO, president, Express Scripts.
The plan will be supported by ValoremRx Specialty Solutions, which will source specialty drugs. This approach will simplify the pharmaceutical supply chain and lower costs for all patients and clients, including Accredo and Walgreens specialty pharmacy patients, according to the release.
For more information, please visit SpecialtyPharmacyTimes.com.
FDA Grants Orphan Drug Designation to MDL-101 for Congenital Muscular Dystrophy Type 1a